Table 1

Patient and clinical characteristics of patients with metastatic cutaneous melanoma receiving ICIs

Patients and clinical characteristicsICIs-R (n=15)ICIs-NR (n=9)P value
Median age at treatment start (years)72±15.8170±12.280.440
Females, n (%)9 (60.00) 2 (22.22)0.105
Males, n (%)6 (40.00)7 (77.78)
Baseline M-stage, n (%)
 M1a1 (6.67)01
 M1b 4 (26.67)2 (22.22)
 M1c-d10 (66.67)7 (77.78)
Baseline LDH
 Median (μkat/L)3.95±1.113.90±7.360.850
 ≤ULN, n (%)8 (53.33)4 (44.44)0.680
 >ULN, n (%)6 (40.00)5 (55.56)
 Missing data, n (%)1 (6.67)0
First-line therapy, n (%)
 Anti-PD-110 (66.67)6 (66.67)0.551
 Anti-CTLA-43 (20.00)3 (33.33)
 Anti-PD-1 and anti-CTLA-42 (13.33)0
Best treatment response, n (%)
 Complete response5 (33.33)0n.a
 Partial response4 (26.67)0
 Stable disease6 (40.00)0
 Progressive disease (no response)09 (100.00)
Progression-free survival, median (days)430±375.2073±37.15<0.001
Overall survival, median (days)809±269.12125±305.24<0.001
  • P-values are obtained with t, Wilcoxon, Fisher, or log-rank test, number after ± is SD.

  • ICIs-NR, patients treated with immune checkpoint inhibitors with no response to treatment; ICIs-R, patients treated with immune checkpoint inhibitors with response to treatment; n.a., not applicable.